Greenland Mines Ltd · NASDAQ:GRML
Greenland Mines — Redwoods Acquisition — SPAC Merger (August 2023)
30 slides from Greenland Mines's SPAC merger presentation, Aug 11, 2023
Slide 1: Using Gene Therapy to Address The Aging Process
Using Gene Therapy to Address The Aging Process Investor Presentation Q3 2023
Slide 2: Disclaimer
Disclaimer 2 This presentation is being furnished solely for the purpose of considering a potential transaction involving Redwoods Acquisition Corp . (“Redwoods”) and Anew Medical, Inc . (“ANEW”) . By accepting this presentation, the recipient acknowledges and agrees that all of the information cont
Slide 3: About the Transaction
@ ANEW MEDICAL, INC. About the Transaction
Slide 4: Transaction Overview
($ millions) ANEW Medical, Inc. (“ANEW”) is expected to combine with Redwoods Acquisition Corp. (“RWOD”) Sources of Funds $5.0 to create a publicly - listed, disruptive gene therapy company PIPE Investment (4) 54.0 ▪ ANEW is a Wyoming corporation with a primary focus on developing disruptive new the
Slide 5: Company Overview
@ ANEW MEDICAL, INC. Company Overview
Slide 6: Mission Statement
6 Mission Statement ANEW MEDICAL, INC. is developing AAV - based gene therapies and disruptive new diagnostics to identify, alleviate and/or reverse the progression of age - related neurodegenerative diseases. We are laser focused on novel anti - aging medicines based on proprietary applications of
Slide 7: Executive Team
7 Exec u tive T eam Dr. Joseph Sinkule Chief Executive Officer & Chairman Dr. Miguel Chillon Rodriguez Chief Scientific Advisor & Director Dr. Shalom Hirschman Chief Medical Advisor & Independent Director Mr. Rick Basse Interim Chief Financial Officer Board of Directors Dr. Samuel Zentman Independen
Slide 8: Investment highlights
• A bioactive Klotho recombinant protein is very difficult to produce . We have produced bioactive Klotho in CHO cells. • To our knowledge, there is no direct competition in the clinic involving human clinical trials of full - length p - KL or truncated “secreted Klotho” or s - KL. • Our “Cognition”
Slide 9: α-Klotho and Longevity: Market Opportunity
α - Klotho and Longevity: Market Opportunity 9 3x Expected increase in population over 80 y/o by 2050. 1 95% Percentage of population over 65 y/o with at least one chronic condition. 2 80% Percentage of population over 65 y/o with two or more chronic conditions. 2 The absence of the α - Klotho gene
Slide 10: Anticipated Development Timeline
10 Anticipated Development Timeline s - K L A A V . m yo optimization s - K L A A V . m y o assay development ALS/AD - Phase 2 - 3 adaptive design Orphan drug ADAD & ALS BLAA/MLA approvals for ALS Klotho in vitro diagnostic CRO/CDMO collaborations - GMP product and ALS & AD sites Launch Klotho diagn
Slide 11: Product Pipeline
11 Product Pipeline Phase II/III Phase I/II IND Preclinical D e v elopme n t Research Potential Indications Product Name ls to d human tria 2024 Anticip a te begin in Q1 Amyotrophic lateral sclerosis (ALS), ataxia AM - 202 [AAVmyo.s - KL] Ge n e T h e rapy Programs Alzheimer’s, ADAD, MCI, Dementia,
Slide 12: Intellectual Property & Know How
12 Intellectual Property & Know How • USPTO Application No .: 15 / 777 , 456 ; Filed : May 18 , 2018 . Title : SECRETED SPLICING VARIANT OF MAMMALIAN KLOTHO AS A MEDICAMENT FOR COGNITION AND BEHAVIOUR IMPAIRMENTS . • USPTO Application No .: 18 / 299 , 989 : Filed : April 13 , 2023 . Title : TREATMEN
Slide 13: Background of α-Klotho and ANEW's Approach to α-Klotho-based Therapies
Background of α - Klotho and ANEW’s Approach to α - Klotho - based Therapies
Slide 14: Advancing Potential α-Klotho-based Therapies
A dvancing Potential α - Klotho - based Therapies 14 ANEW’s focus is to bring to market groundbreaking α - Klotho gene and cellular therapies, utilizing novel methods of gene and protein delivery for aging - related diseases and disorders . The α - Klotho gene was discovered in 1997 by Dr. Kuro - O
Slide 15: α-Klotho Proposed Mechanisms of Action
α - Klotho Proposed Mechanisms of Action 5 ,6 15 ▪ Inhibits inflammatory cytokines in brain & CNS. ▪ Promotes anti - inflammatory cytokines. ▪ Binds APP & protects CN S against amyloid toxicity. ▪ Autophagy clearance of amyloid & tau tangles (cell debris). ▪ Protects Neurons from Death ▪ Oxidative s
Slide 16: The Secreted Klotho Isoform (s-KL)
The Secreted Klotho Isoform (s - KL) 16 The 5 exon Klotho (KL) gene on human chromosome 13 produces 2 different Klotho transcripts : 1. A transmembrane Klotho ( m - KL ), which may be metabolized further to a dimer termed p - KL . … and 2. Secreted - KL (s - KL ) , which is produced directly from th
Slide 17: Preclinical Studies & Results
Preclinical Studies & Results
Slide 18: Lead Disease Indications & Indication Selection Rationale
Lead Disease Indications & Indication Selection Rationale 18 • Target Product Profile – ALS using AAVmyo.s - KL (ANEW 202) • Urgent medical need, no satisfactory treatment, and “rare disease” benefits. • Amyotrophic Lateral Sclerosis (ALS) is a progressive neurologic disorder characterized by the lo
Slide 19: Published Results and Know How
Published Results and Know How 19 Our Barcelona team has over 25 years of experience selectively manipulating levels of therapeutic proteins like s - KL and m - KL in vivo by using gene therapy strategies.
Slide 20: α-Klotho as a Biomarker and Diagnostic
α - Klotho as a Biomarker and Diagnostic – 2 Examples 20 9, 10 Highly significant differences Highly significant differences at p=0.006 Our in vitro diagnostic will measure blood levels of Klotho protein & gene, and the test results used to predict disease status and the need for treatment with our
Slide 21: Data & Results – Aging and Cognition Mice Models
Data & Results – Aging and Cognition Mice Models 11 21 • Th e s e c rete d Kl oth o is ofor m ( s - KL ) i s a l mo s t e x cl u siv e l y ( > 90 % ) foun d in the brain and high expression levels of s - KL corelate with brain health and healthy aging. • We have leveraged AAV - based vectors to targ
Slide 22: Data & Results – Aging and Cognition Animal Models
Data & Results – Aging and Cognition Animal Models 12 22 • In the brain, s - KL expression reduced neuroinflammation and normalized the levels of inflammatory markers and recovered normal levels of brain’s immune system cells in rodents. • Long - term expression of s - KL did not induce secondary si
Slide 23: Summary of Results in Murine ALS/Neuromuscular disease model
Summary of Results in Murine ALS/Neuromuscular disease model 13 23 ↑ Amplitude of the muscle action potentials Improved the connectivity between cortex and spinal motor neurons Enhanced motor c oo r d i n at io n a n d balance Improved grip strength Delayed disease onset Promoted muscle end - plates
Slide 24: AAV.myo Concentrates in Mouse Muscle Tissue
14 Grimm, et al . 2020 AAV.myo Concentrates in Mouse Muscle Tissue 14 24 Very high concentrations of AAV.myo in major muscles in both mice and non - human primates (NHP). ANEW licensed this AAV.myo vector for the delivery of our payload to human muscle tissue and the neuromuscular junction for ALS t
Slide 25: AAV.myo Concentrates in Mouse Muscle Tissue
AAV.myo Concentrates in Mouse Muscle Tissue 14 25 “Regular” AAV9 is high in liver compared to our licensed AAV.myo vector. ANEW licensed this AAV.myo vector for the delivery of our payload to human muscle tissue and the neuromuscular junction for ALS treatment. 14 Grimm, et al . 2020
Slide 26: Conclusion
@ ANEW MEDICAL, INC. Conclusion
Slide 27: Conclusion highlights
• A bioactive Klotho recombinant protein is very difficult to produce . We have produced bioactive Klotho in CHO cells. • To our knowledge, there is no direct competition in the clinic involving human clinical trials of full - length p - KL or truncated “secreted Klotho” or s - KL. • Our “Cognition”
Slide 28: References
Ref e rences Slide 9 1 NIH Report: “An Aging World: 2015”. Wan He, Daniel Goodkind, and Paul Kowal. U.S. Census Bureau, International Population Reports, P95/16 - 1, U.S. Government Publishing Office, Washington, DC, 2016. 2 National Council on Aging. Chronic Inequities: “Measuring Disease Cost Burd
Slide 29: References (continued)
Ref e rences Slide 20 (continued) 9 “Klotho in the cerebrospinal fluid of adults with and without Alzheimer's disease”. Semba, et.al. Published in final edited form as: Neurosci Lett. 2014 January 13; 558: 37 – 40. doi:10.1016/j.neulet.2013.10.058. 10 “Plasma Klotho and Cognitive Decline in Older Ad
Slide 30: ANEW Medical, Inc.
@ ANEW MEDICAL, INC.